Top entities: Illumina — Holy Grail, Hagens Berman, Reed Kathrein, United States — United States Securities and Exchange Commission.

What category does this event fall under?

Regulatory — classified as securities class action.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Illumina — Holy Grail announced trial endpoint not observed · Hagens Berman filed class action Illumina — Holy Grail

Is this event still developing?

This is an active story, last updated Jul 15, 2026. Coverage continues to evolve.

Regulatory securities class action

GRAIL securities class action lawsuit

Q: When did this event occur?

First reported Jul 08, 2026; last updated Jul 15, 2026.

Q: What is the market impact?

General. GRAIL's stock plummeted over 50% following the trial failure, wiping out $2.

Analysis based on 7 articles · First reported Jul 08, 2026 · Last updated Jul 15, 2026

Sentiment

-40

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

GRAIL's stock plummeted over 50% following the trial failure, wiping out $2.2 billion in market cap. The class action lawsuit may result in significant financial penalties and further damage investor confidence in the company.

Healthcare Biotechnology

Event Summary

GRAIL, Inc., a commercial-stage healthcare company focused on early cancer detection, faced a securities class action lawsuit after its NHS-Galleri Trial failed to achieve its primary endpoint on February 19, 2026. The company's stock price dropped over 50% the next day, erasing over $2.2 billion in market capitalization. The lawsuit, filed by Hagens Berman, alleges that GRAIL and its executives misled investors about the trial's design and likelihood of success during the class period from May 13, 2025 to February 19, 2026. The complaint claims that GRAIL had information suggesting that a three-year follow-up period was insufficient but continued to express high confidence. The lead plaintiff deadline is August 4, 2026.

Key Actions

100 Illumina — Holy Grail announced trial endpoint not observed

80 Hagens Berman filed class action Illumina — Holy Grail

Entities Involved

subs

Illumina — Holy Grail

GRAIL is the defendant in the securities class action; its stock crashed after trial failure, and it faces potential liability.

Importance 100.0 Sentiment -80.0

priv

Hagens Berman

Hagens Berman is the law firm representing investors in the class action against GRAIL.

Importance 60.0 Sentiment 10.0

per

Reed Kathrein

Reed Kathrein is the Hagens Berman partner leading the investigation of the claims against GRAIL.

Importance 30.0 Sentiment 0.0

govactor

United States — United States Securities and Exchange Commission

The SEC's whistleblower program is mentioned as a potential avenue for reporting, but the SEC is not directly involved in the lawsuit.

Importance 20.0 Sentiment 0.0

Relationships

Hagens Berman related ↔ Reed Kathrein

Hagens Berman related ↔ United States — United States Securities and Exchange Commission

Reed Kathrein related ↔ United States — United States Securities and Exchange Commission

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard